Hims & Hers Health: Could Start To Look Interesting In 2026 [Seeking Alpha]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Seeking Alpha
HIMS faces near-term headwinds from GLP-1 partnership termination and FDA scrutiny, but has catalysts in hormone health, women's health, and lab diagnostics. Q3 saw 49% YoY revenue growth, 74% gross margin, and robust subscriber and revenue-per-user gains, supporting the company's compounding flywheel model. Despite a sharp selloff and high short interest, I see significant upside if HIMS executes on diversification, internal fulfillment, and risk mitigation. The Good Brigade/DigitalVision via Getty Images Even though Hims & Hers Health, Inc. ( HIMS ) had a successful 2025 leading to more than 30% appreciation, shares of HIMS are well off their 52-week highs. Shares of HIMS have fallen -54.22% since, reaching $72.98, and the short interest This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article my
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers And HIMZ: Short-Term Pain From Novo, Long-Term Opportunity Still Bright [Seeking Alpha]Seeking Alpha
- BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS) [Yahoo! Finance]Yahoo! Finance
- Hims & Hers: Growth Catalysts Or Margin Trap [Seeking Alpha]Seeking Alpha
- Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health (NYSE:HIMS) is now covered by analysts at Evercore ISI. They set an "in-line" rating and a $33.00 price target on the stock.MarketBeat
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 1/7/26 - Form 4
- 12/23/25 - Form 4
- 12/22/25 - Form 144
- HIMS's page on the SEC website